Compass Therapeutics, Inc. — Form D
Compass Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-01. The offering totals $70.0M, of which $60.5M was reported sold. Industry: Other.
Offering
- Filed: 2020-07-01
- Form: D
- Accession: 0001802806-20-000004
- Industry: Other
- Exemptions: 06b
- Total offering: $70.0M
- Amount sold: $60.5M
- Remaining: $9.5M
- Investors: 110
- Date of first sale: 2020-06-19
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-370115
Issuer
- Name: Compass Therapeutics, Inc.
- CIK: 0001738021
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2018
- Address: 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142
- Phone: 617-500-8099
Officers, directors & promoters (7)
| Name | Role | Location |
|---|
| PHILIP J FERNEAU | Director | CAMBRIDGE, MA |
| Carl L Gordon | Director | Stamford, CT |
| THOMAS J SCHUETZ | Director | CAMBRIDGE, MA |
| Stephen P Squinto | Director | New York, NY |
| Julie Sunderland | Director | CAMBRIDGE, MA |
| Vered P Bisker-Leib | Executive Officer | Cambridge, MA |
| THOMAS J SCHUETZ | Executive Officer | CAMBRIDGE, MA |
Other filings by this issuer (1)
More